Description
Valdecoxib is a COX inhibitor specific for COX-2; it also inhibits carbonic anhydrase. Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory and analgesic activities. In addition to its mediation of inflammatory signaling, valdecoxib also activates cannabinoid 1 (CB1) receptors in vivo, modulating glutamate signaling and GABA release. Valdecoxib has been removed from clinical use due to increased risk of thrombotic effects.